ArticleMolecular biology reports2026
Investigation of miRNAs affecting schwann cells in patients with trigeminal neuralgia.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTrigeminal neuralgia (TN) is a debilitating neuropathic pain disorder characterized by severe paroxysmal facial pain. Increasing evidence indicates that Schwann cell dysfunction and altered nerve repair mechanisms contribute to TN pathology. MicroRNAs (miRNAs), as key regulators of Schwann cell plasticity, myelination, inflammation, and nerve regeneration, represent promising biomarker candidates. This study aimed to investigate differential expression patterns of Schwann cell-associated miRNAs (miR-221-3p, miR-132-3p, miR-210-5p, miR-340-3p, miR-98-5p, miR-182-5p) in patients with trigeminal neuralgia and evaluate their diagnostic biomarker potential. METHODS AND
resultsExpression analysis was performed using quantitative real-time PCR with 5s rRNA as the reference gene. miRNA expression levels were evaluated by qRT-PCR. Differential expression was calculated using ΔCt, ΔΔCt, and fold-change analyses. Diagnostic performance was assessed using ROC curve analysis. Integrated visualization was carried out using scatter plots, volcano plots, and z-score-normalized heatmaps. miR-221-3p was significantly upregulated in patients with trigeminal neuralgia (TN), whereas miR-340-3p and miR-182-5p were downregulated. Hierarchical clustering and principal component analysis (PCA) demonstrated a clear separation between patient and control miRNA expression profiles. In receiver operating characteristic (ROC) analyses, miR-221-3p emerged as the most powerful individual biomarker (AUC = 0.699), while the combined miRNA panel achieved high diagnostic performance (AUC = 0.89). Downregulated miRNAs reflect suppressed inhibitory signaling pathways, suggesting that miRNA profiling may provide valuable insights into Schwann cell pathology in TN.
conclusionsThe selected miRNAs, which are implicated in impaired Schwann cell repair mechanisms, represent promising molecular biomarker candidates for the diagnosis of TN and potentially for guiding therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.